Schering Corporation

Harbor Branch Oceanographic Institution, Inc.

Vincent P Gullo

Mahesh G Patel

Ann C Horan

Stephen J Coval

Shirley A Pomponi

George H Miller

David Loebenberg

Roberta S Hare

Heewon Y Kwon

Min Chu

Jerome Schwartz

Shirley A Pompni

James B Morton

An aqueous pharmaceutical composition comprising a lipophilic oligosaccharide antibiotic salt, e.g., the N-methylglucamine salt of the everninomicin-type antibiotic of Formula III together with a binding agent such as human serum albumin or recombinant human albumin and a tonicity agent such as mannitol, is disclosed.

Lipophilic oligosaccharide antibiotic compositions

Lipophilic oligosaccharide antibiotic salt compositions

A method of treating mammals infected with HIV-1, or AIDS by administering a therapeutically effective amount of a compound represented by formula I ##STR1## or a pharmaceutically acceptable salt or ester thereof or stereoisomer thereof and pharmaceutical compositions containing it are disclosed.

Method and composition for treating HIV-type 1 infections

Compounds of the formula: ##STR1## wherein a is a single bond and b is a double bond; or a is a double bond and b is a single bond; and enantiomers thereof; or a pharmaceutically acceptable salt thereof are described. These compounds can improve lipoprotein profile of dyslipidemic patients and generate an anti-atherogenic lipoprotein profile of normolipidemic individuals. In addition, inhibition of CETP activity may be useful as antifertility agents.

Anti-dyslipidemic agents

A method for treating airway congestion which comprises administering an effective amount of the compound of formula II which follows ##STR1## or a pharmaceutically acceptable salt thereof.

Method for treating airway congestion

Four bicyclic terpenes isolated from a culture broth of Phoma sp SCF0592, ATCC 74077, pharmaceutical compositions containing them and their use as PAF antagonists to treat allergic and inflammatory diseases are disclosed.

Bicyclic diterpene PAF antagonist compounds

The compound of the formula ##STR1## is described. This compound is active in an H.sub.3 receptor assay and is an H.sub.3 antagonist. Accordingly, the compound of formula I is useful in the treatment of diseases and conditions such as asthma, rhinitis, airway congestion, inflammation, cardiac arrhythmias, hypertension, hyper and hypo motility and acid secretion of the gastrointestinal tract, hypo and hyper activity of the central nervous system (CNS), migraine, and glaucoma.

Growing community of inventors

Liberty Corner, NJ, United States of America

Vincent P Gullo